292 results about "D-GLUCURONIC ACID" patented technology

The invention discloses a lactobacillus mucus fermentation strain and application thereof, and provides a lactobacillus mucus fermentation strain A10 with high yield of exopolysaccharides, and the preservation number of the lactobacillus mucus fermentation strain A10 is CCTCC (China Center for Type Culture Collection) NO: M20242082. The fermented lactobacillus mucus A10 has relatively strong bile salt and gastrointestinal tract digestion tolerance and has an obvious antibacterial effect on escherichia coli and staphylococcus aureus, and the exopolysaccharide synthesized by the fermented lactobacillus mucus A10 is Wzy type exopolysaccharide, is heteropolysaccharide composed of rhamnose, galactose, glucose, mannose and glucuronic acid, and can be used for preparing the exopolysaccharide. The product has good thermal stability and antioxidant activity, and can significantly scavenge free radicals. The lactobacillus mucus A10 extracellular polysaccharide provided by the invention can exert antioxidant activity by activating a Keap1-Nrf2 / ARE signal channel, and is expected to be developed into a natural antioxidant which interacts with Keap1-Nrf2 in a targeting manner.

The invention provides homogenized pitaya polysaccharide as well as a preparation method and application thereof, and belongs to the technical field of polysaccharide extraction and purification. The homogenized pitaya polysaccharide is a polysaccharide of which the monosaccharide is composed of mannose, glucosamine hydrochloride, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose, the relative molecular weight is 8.08 * 10 < 4 > Da, and the corresponding molar ratio is (0.181): (0.250): (16.544): (12.762): (3.793): (0.739): (51.014): (14.716). The invention further provides a preparation method of the homogenized pitaya polysaccharide and application of the homogenized pitaya polysaccharide in preparation of lipid-lowering and sugar-lowering drugs. The homogenized pitaya polysaccharide disclosed by the invention has an obvious lipid-lowering and blood-glucose-reducing effect, is from a natural product, so that the homogenized pitaya polysaccharide has no toxic or side effect and can be used for preparing lipid-lowering and blood-glucose-reducing medicines.

The invention discloses application of a ganoderma lucidum strain SS30 in preparation of a product for treating cancers, and belongs to the technical field of biology. The invention provides ganoderma lucidum strain SS30 mycelium polysaccharide. The ganoderma lucidum strain SS30 mycelium polysaccharide is prepared from glucose, galactose, mannose, fucose, xylose, arabinose, rhamnose, glucuronic acid, glucosamine, ribose and lacturonic acid. The polysaccharide has a remarkable effect of inhibiting transplantable pancreatic cancer and primary colorectal cancer, can achieve the effect of treating cancer by improving the immune function and reducing the oxidation product generation level, provides a new material for development and utilization of lucid ganoderma and products thereof, and has a wide application prospect. And a research basis is provided for research and development of cancer-related drugs and research of a cancer treatment mechanism.

The invention relates to the field of establishment of fingerprints of traditional Chinese medicinal materials, in particular to an establishment method and application of a salvia miltiorrhiza polysaccharide HPLC (High Performance Liquid Chromatography) fingerprint. The establishment method comprises the following steps: preparation of a test solution: taking a salvia miltiorrhiza polysaccharide hydrolysis solution, carrying out derivatization in a reaction bottle, and passing through a 0.1-0.3 [mu] m microporous filter membrane; preparing a reference substance solution, namely weighing mannose, ribose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose reference substances, and preparing into a mixed reference substance solution; performing HPLC (high performance liquid chromatography) determination; and establishing the salvia miltiorrhiza polysaccharide HPLC fingerprint spectrum. According to the method, the difference of monosaccharide composition and content in salvia miltiorrhiza medicinal materials from different producing areas and the spectrum-effect relationship between antioxidant activity and anticoagulant activity are clarified, and a certain reference basis is provided for quality control and evaluation of the salvia miltiorrhiza medicinal materials from the aspect of polysaccharide.

The invention relates to gardenia polysaccharide as well as a preparation method and application thereof. The gardenia polysaccharide comprises the following monosaccharide units: rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose, or mainly comprises rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose; the molar ratio of rhamnose to glucuronic acid to galacturonic acid to glucose to galactose to arabinose in the gardenia polysaccharide is (3-15): (1-8): (4-18): (1-6): (15-35): (25-70). According to the gardenia polysaccharide, FFA induced mouse primary parenchymal hepatic cell lipid accumulation can be reduced, no obvious cytotoxic effect exists, CDAHFD diet induced hepatic fibrosis can be reduced, and the gardenia polysaccharide has a good effect of preventing and / or treating non-alcoholic steatohepatitis.

The invention discloses an inositol oxidase mutant and application thereof, and belongs to the technical field of gene engineering. The inositol oxidase mutant is obtained by mutating 113th amino acid of an amino acid sequence shown as SEQ ID NO.1, and the mutation is that the 113th amino acid is mutated from T to A. The enzyme activity of the inositol oxidase mutant is remarkably improved, the thermal stability is good, the half-life period is long, and the yield and conversion rate of glucuronic acid can be improved.

The present invention discloses a fermented mucus lactobacillus and its application. The present invention provides a fermented mucus lactobacillus A10 with high extracellular polysaccharide production, and its deposit number is CCTCC NO: M20242082. The fermented mucus lactobacillus A10 has strong bile salt and gastrointestinal digestion tolerance, and has obvious antibacterial effects on Escherichia coli and Staphylococcus aureus. The extracellular polysaccharide synthesized by the fermented mucus lactobacillus A10 is a Wzy type extracellular polysaccharide, which is a heteropolysaccharide composed of rhamnose, galactose, glucose, mannose, and glucuronic acid. It has good thermal stability and antioxidant activity, and can significantly scavenge free radicals. The fermented mucus lactobacillus A10 extracellular polysaccharide provided by the present invention can exert antioxidant activity by activating the Keap1-Nrf2 / ARE signaling pathway, and is expected to be developed into a natural antioxidant that interacts with Keap1-Nrf2 in a targeted manner.

The present invention relates to a recombinant yeast cell that produces UDP-D-glucuronic acid and / or UDP-N-acetyl-D-glucosamine compared to a wild type cell of the recombinant yeast cell; and optionally, the yield of 3 '-phosphate-adenylate sulfuric acid is increased. The invention also relates to a method for producing heparan sulfate, which comprises a step of culturing the recombinant yeast cell, further relates to an application of the non-invasive recombinant yeast cell for producing heparan sulfate, and finally relates to heparan sulfate obtained by applying the method.

The invention discloses a genetically engineered bacterium for producing glucuronic acid as well as a construction method and application of the genetically engineered bacterium, and belongs to the technical field of genetic engineering. According to the genetically engineered bacterium for producing glucuronic acid, an inositol oxidase gene MMIOX is integrated on a site of a uronic acid isomerase gene uxaC. According to the invention, an inositol oxidase gene MMIOX is integrated on a genome of a genetically engineered bacterium for producing glucuronic acid, and a uronic acid isomerase gene uxaC is knocked out at the same time, so that the genetically engineered bacterium can efficiently catalyze inositol reaction to generate glucuronic acid through the integrated inositol oxidase gene MMIOX; the glucuronic acid isomerase gene uxaC is knocked out, so that isomerization reaction of glucuronic acid can be avoided, and the yield of glucuronic acid is further increased.

The invention relates to the field of medicines, foods or health-care products, in particular to big-fruit hawthorn heteropolysaccharide as well as a preparation method and application thereof. The large-fruit hawthorn heteropolysaccharide is prepared from galacturonic acid, glucuronic acid, mannose, xylose, arabinose, glucose, galactose, fucose and rhamnose. The weight-average molecular weight of the big fruit hawthorn heteropolysaccharide is 81.6 kDa to 157.3 kDa. The product has unique structures of complex monosaccharide composition, low molecular weight, appropriate uronic acid content, low esterification degree and the like; compared with CP which is single in structure and high in esterification, the CP is better in oxidation resistance and bile acid binding capacity; compared with hawthorn polysaccharide with low uronic acid content and high molecular weight, the hawthorn polysaccharide has the advantages that the enzyme inhibition activity is obviously enhanced, and the hawthorn polysaccharide has a wide prospect in development of functional food, health care products or medicines for regulating blood sugar / blood fat, resisting oxidation and preventing metabolic syndromes.

The invention relates to the technical field of diagnosis markers and diagnosis methods for mental diseases of children and adolescents, in particular to a plasma metabolism diagnosis marker and diagnosis system for depression of children and adolescents. The plasma metabolism diagnosis marker comprises at least one of cyclic adenosine monophosphate, methylpyridine, unsaturated undecylenyl carnitine, histidine, prolyl hydroxyproline, tryptophan and glucuronic acid. According to the scheme, non-target metabonomics data is analyzed, and seven candidate diagnostic markers for depression of children and adolescents are screened and determined from common differential metabolites. Then, through targeted metabonomics research, diagnostic markers and combinations thereof with ideal diagnostic effects are determined, and then a diagnostic model is constructed. And a sex factor is also incorporated into the diagnosis model, so that the diagnosis effect is further improved. According to the technical scheme, the technical problem that in the prior art, reliability and popularization potential of depression plasma metabolism biomarkers of children and adolescents are not ideal can be solved, and the depression plasma metabolism biomarkers have ideal popularization and application prospects.

The invention discloses a polysaccharide compound of Alsophila spinulosa and an extraction method and application thereof, wherein the polysaccharide compound is composed of rhamnose, arabinose, galactose and glucuronic acid. The polysaccharide compound of the invention is derived from mature leaves of Alsophila spinulosa, and is extracted by water extraction and alcohol precipitation, crude polysaccharide impurity removal, DEAE seplife FF ion column separation, and Sephacryl S‑400HR gel column purification. The method is simple and fast to operate, and water extraction and anhydrous ethanol precipitation are mainly used in the extraction and separation process. The process method is environmentally friendly, and the purity of the compound separated by the method is relatively high, all greater than 92%. The extracted polysaccharide compound has been found to have a significant hypoglycemic effect through research, and can be used as a raw material for new drug development and pharmacological activity research, and can also be used for food additives or health care product development.

The invention relates to the technical field of plant polysaccharides, and particularly discloses a red-knees herb polysaccharide and a preparation method and application thereof, the peak top molecular weight of the red-knees herb polysaccharide is 33.9 KDa, the weight-average molecular weight of the red-knees herb polysaccharide is 42.8 KDa, the number-average molecular weight of the red-knees herb polysaccharide is 10.0 KDa, and the red-knees herb polysaccharide is mainly composed of galacturonic acid, galactose, arabinose, rhamnose and glucuronic acid. According to the preparation method of the red-knees herb polysaccharide, by optimizing process parameters and controlling the reasonable solid-liquid ratio, heating temperature and heating time, the dissolution rate of the polysaccharide is increased, the dissolution rate of impurities is reduced, and the yield of the red-knees herb polysaccharide is increased. The red-knees herb polysaccharide is used as a raw material, ethanol is used for alcohol precipitation, polysaccharide components are precipitated, impurities are preliminarily removed, then macroporous resin is used for purification, the recovery rate of polysaccharide and the removal rate of impurities such as pigment and protein are improved by screening optimization and pretreatment of the macroporous resin, and the total sugar content of the purified red-knees herb polysaccharide is 80% or above. Use of toxic chemical reagents is avoided, and the preparation method is safe and efficient.

The invention discloses a gymnadenia conopsea octasaccharide-decaose mixture as well as a preparation method and application thereof, and belongs to the technical field of medicines. The monosaccharide of the octasaccharide-decataccharide mixture of the gymnadenia conopsea comprises N-acetamino galactose, fucose, glucuronic acid or sugar alcohol thereof, galactose, N-acetylglucosamine, dehydrated talose and a sulfate group. The octasaccharide to decataccharide mixture of the gymnadenia conopsea disclosed by the invention can be used for remarkably prolonging the time of activating partial thromboplastin and prothrombin and effectively inhibiting endogenous and common coagulation pathways. The octasaccharide-decaose mixture of the gymnadenia conopsea can be used as a potential endogenous factor X enzyme inhibitor for preparing medicines for treating thrombotic cardiovascular diseases.

The invention discloses an extraction process and a quality control method of acanthopanax senticosus polysaccharide and application of the acanthopanax senticosus polysaccharide. The acanthopanax senticosus polysaccharide is prepared from acanthopanax senticosus roots, stems, leaves and fruits through a water extraction and alcohol precipitation extraction method. The polysaccharides of the roots, the stems, the leaves and the fruits of the acanthopanax senticosus all contain monosaccharides which comprise 5.0% to 50% of D-mannose, 0.7% to 6.0% of L-rhamnose, 4.0% to 33% of D-glucuronic acid, 6.0% to 69% of D-glucose, 13% to 40% of D-galactose and 4.0% to 18% of D-arabinose. The quality control method ensures the quality of the acanthopanax senticosus. A standard for controlling the acanthopanax senticosus polysaccharide is established by analyzing chemical components of the acanthopanax senticosus polysaccharide, content limitation of core components of the acanthopanax senticosus polysaccharide is added to the standard, and the polysaccharide prepared from the acanthopanax senticosus selected according to the range is used for judging polysaccharides of the acanthopanax senticosus and other plants and different parts of the acanthopanax senticosus. The method is good in reproducibility, accurate and reliable, and the acanthopanax senticosus polysaccharide and medicinal materials of different parts of acanthopanax senticosus can be rapidly and accurately identified through infrared characteristics and monosaccharide composition.

The invention discloses a raspberry homogeneous polysaccharide. The monosaccharide components of the raspberry homogeneous polysaccharide comprise fucose, rhamnose, arabinose, galactose, xylose, galacturonic acid, glucuronic acid and apiose. The main chain structure of the raspberry homogeneous polysaccharide is 1, 4-linked galacturonic acid pyranose, and the weight-average molecular weight of the raspberry homogeneous polysaccharide is 8.54 + / -5.0 kDa. The invention discloses a raspberry homogeneous polysaccharide component for inhibiting dietary oil absorption and preventing and improving obesity, which is prepared by the steps of water extraction and alcohol precipitation, ion exchange chromatographic column elution and permeation gel chromatographic column elution. The structure of the compound is analyzed by high performance gel permeation chromatography, infrared spectroscopy, ion chromatography, gas chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy. The homogeneous polysaccharide component can be used for improving obesity and fat tissue accumulation hypertrophy, and the efficacy of the homogeneous polysaccharide component is related to inhibition of absorption of dietary oil in the intestinal tract and promotion of discharge of the dietary oil into the body.

The invention discloses enteromorpha oligosaccharide as well as a preparation method and application thereof. The enteromorpha oligosaccharide is prepared by degrading enteromorpha polysaccharide, the polymerization degree is 2-10, the enteromorpha oligosaccharide contains rhamnose, glucose, glucuronic acid and xylose, and the preparation method is simple. By constructing a type 2 diabetes mellitus mouse model, it is verified for the first time that the enteromorpha oligosaccharide can significantly reduce the fasting blood glucose level of the type 2 diabetes mellitus mouse, reduce the insulin content in serum and the glycated serum protein level, improve the blood fat metabolism capability of the type 2 diabetes mellitus mouse, and improve the activity of the enteromorpha oligosaccharide in the type 2 diabetes mellitus mouse. According to the enteromorpha oligosaccharide, the liver glycogen synthesis capacity in the mouse liver is improved, the abnormal liver function of the mouse with the type 2 diabetes mellitus is improved, the safety of the enteromorpha oligosaccharide is high, and the enteromorpha oligosaccharide has a good prospect in the aspect of developing food or drugs with the function of controlling the type 2 diabetes mellitus.

The invention discloses arabinose glycosyl transferase PnUGT73B4 and application thereof to preparation of panax japonicus saponin IV, the amino acid sequence of the arabinose glycosyl transferase is shown as SEQ ID NO: 1, under the catalysis of the arabinose glycosyl transferase PnUGT73B4, UDP-arabinose is added to a glucuronic acid group on the C3 site of panax japonicus saponin IVa, and the panax japonicus saponin IV is generated; according to the method, the requirement for raw material plants can be reduced, agricultural land is saved, the product is single, preparation of the panax japonicus saponin IV is facilitated, the biosynthesis route of oleanane type triterpenoid saponin is analyzed, and a breakthrough solution is provided for biosynthesis of the panax japonicus saponin IV.

The invention relates to the field of microbial strains edited by gene recombination and synthetic biology, and provides recombinant escherichia coli for synthesizing D-xylose by using glucose and application. The recombinant escherichia coli comprises the following modifications: exogenous insertion of a gene IRX for coding beta-1, 4-xylosyltransferase; exogenous insertion of a gene UXS encoding a UDP-glucuronic acid decarboxylase; the invention relates to enhanced expression or overexpression of a gene yagH for coding beta xylosidase. Compared with a traditional hemicellulose hydrolysis method for producing D-xylose, the method for synthesizing and preparing D-xylose through whole-cell catalysis of D-glucose by using the recombinant escherichia coli has the advantages of environmental protection, cost advantage and energy saving.

The invention belongs to the technical field of ocean, and particularly relates to sea cucumber polysaccharide with an anti-colitis effect and application of the sea cucumber polysaccharide. According to the invention, the holothuria leucospilota polysaccharide H.leucospilota PS with a brand new structure is separated and purified from holothuria leucospilota, and the holothuria leucospilota polysaccharide H.leucospilota PS is composed of five monosaccharides, namely glucosamine, glucuronic acid, galactosamine, galactose and fucose. According to the present invention, by changing the intestinal microflora structure, the polysaccharide further regulates the generation of 3-Hydroxybutyrate, L-Meliic acid and Succinic semialdehydes, such that the intestinal energy metabolism is regulated, the intestinal microflora disorder and the energy metabolism disorder caused by the colitis are improved, and the drug resistance and the side effect caused by the long-term taking of the colitis treatment agent can be avoided;

The invention relates to the technical field of biology, in particular to a recombinant strain for producing glucuronic acid and application of the recombinant strain. The invention provides a recombinant strain for producing glucuronic acid, and the recombinant strain does not express uronic acid isomerase and overexpresses inositol oxidase. The technical scheme of the invention has the following advantages: (1) uronic acid isomerase uxaC from escherichia coli K12 is knocked out, so that glucuronic acid accumulation is increased; and (2) successfully integrating the target gene of the inositol oxidase from the mouse into the escherichia coli K12MG1655. And (3) when the engineering strain is used for catalyzing inositol, the content of glucuronic acid in a system after the reaction is finished is 52.50 g / L, and the conversion rate is as high as 97.23%.

The invention relates to the technical field of medicines, and provides sea sodium polysaccharide, a preparation method and application thereof, and an anticoagulant and / or antithrombotic drug of a targeted endogenous coagulation pathway. The sea sodium polysaccharide provided by the invention is fucosylated chondroitin sulfate polysaccharide, the weight-average molecular weight is 90000-130000, the molar ratio of glucuronic acid to N-acetylgalactosamine to fucose is 1: (0.8-1.2): (0.5-0.8), and the mass percentage of sulfate group is 25-40%. The sea sodium polysaccharide provided by the invention can act on a terminal rate-limiting enzyme (iFXase) in an endogenous blood coagulation pathway in a targeting manner, is not obvious in effect on blood coagulation factors in other blood coagulation pathways, realizes the effects of anticoagulation and no bleeding, can be widely applied to acute-stage and recovery-stage treatment of cerebral arterial thrombosis, and has a wide application prospect. The problem of safety of anticoagulant and antithrombotic drugs used by clinical cerebral arterial thrombosis patients is solved, and a new field of research and development of targeted endogenous coagulation pathway rate-limiting enzyme anticoagulant drugs is developed.

The invention belongs to the field of biological medicine, and particularly relates to a polysaccharide modified liposome nano vaccine as well as a preparation method and application thereof. The polysaccharide modified lipidosome nano vaccine is composed of an anionic polysaccharide shell containing a D-glucuronic acid skeleton and a drug-loading cationic lipidosome inner core coated in the polysaccharide shell, and the cationic lipidosome inner core is loaded with an anionic antigen OVA. The polysaccharide-modified lipidosome nano vaccine containing the sulfuric acid acetyl structure has more excellent capability of overcoming inherent barriers of lung mucosa vaccines, and has the advantages of good stability in a lung microenvironment, high biological safety, capability of enhancing in-vivo triple immunity (cell, body fluid and mucosa reaction) and the like; the method has a wide prospect in lung vaccine development and design, and can also be used for vaccine delivery of other administration routes.

The invention discloses raspberry leaf polysaccharide as well as a preparation method and application thereof. The average relative molecular weight of the raspberry leaf polysaccharide is 44755 Da, and the raspberry leaf polysaccharide is mainly prepared from mannose, glucose, rhamnose, glucosamine, galactosamine, glucuronic acid, galactose, xylose and arabinose according to the molar ratio of (3.138): (0.894): (12.349): (4.590): (26.498): (18.681): (22.842): (2.690): (8.317). Besides, methylation and nuclear magnetic resonance analysis show that the raspberry leaf polysaccharide is complex polysaccharide, and it can be reasonably deduced that the raspberry leaf polysaccharide is mainly composed of a large number of HG structural domain-like structures and a part of RG-I structures with side chains. Meanwhile, the raspberry leaf polysaccharide disclosed by the invention can be used for inhibiting the injury of kidney tissues and reducing the generation of kidney inflammatory factors.

The invention provides application of pitaya peel polysaccharide in preparation of a medicine for repairing skin wounds. The monosaccharide components of the pitaya peel polysaccharide comprise rhamnose, arabinose, galactose, glucose, xylose, mannose, galacturonic acid and glucuronic acid. Research finds that the dragon fruit peel polysaccharide remarkably accelerates the wound healing process and promotes granulation tissue formation and collagen deposition. Meanwhile, the pitaya peel polysaccharide can also promote cell proliferation and neovascularization at the skin wound part, exert an anti-inflammatory effect, remodel skin microbiota and provide a more suitable microenvironment for skin wound healing. The invention provides a new drug choice for clinically repairing skin wounds, and can be used for developing new skin wound dressings.

The invention provides recombinant escherichia coli for synthesizing glucuronic acid by using glucose and a method for producing glucuronic acid by using the recombinant escherichia coli, and belongs to the field of microbial metabolic engineering. The engineering bacterium is obtained by taking escherichia coli as an original strain and knocking out a glucuronic acid isomerase coding gene uxaC, a 6-phosphofructokinase I coding gene pfkA, a 6-phosphofructokinase II coding gene pfkB and a glucose-6-phosphate dehydrogenase coding gene zwf. The engineering bacterium disclosed by the invention has a good application prospect in industrial production of glucuronic acid.

The invention discloses low-molecular-weight fucoidin as well as a preparation method and application thereof. The low-molecular-weight fucoidin comprises 52%-65% of polysaccharide, 32%-47% of sulfate radical, 0-2% of glucuronic acid and 0-1% of protein. And the average molecular weight is 2.0-4.5 kDa. The low-molecular-weight fucoidin prepared by a specific extraction, separation and degradation method can resist obesity induced by high fat, the content of fasting blood-glucose, total cholesterol, triglyceride and low-density lipoprotein cholesterol is reduced, meanwhile, the relative abundance of obesity negative correlation flora is promoted, and the relative abundance of obesity positive correlation flora is inhibited; therefore, obesity development is prevented, and the compound has a huge application prospect in candidate drugs for preventing and / or treating obesity.

The invention discloses pleurotus citrinopileatus polysaccharide as well as a preparation method and application thereof. The pleurotus citrinopileatus polysaccharide is hydrolyzed to obtain a mixture containing glucose, galactose and glucuronic acid. Compared with common edible fungus polysaccharide, the pleurotus citrinopileatus polysaccharide provided by the invention can be used as a carbon source to be specifically utilized by parabacteroides gobi so as to promote metabolism and proliferation of the parabacteroides gobi, and can be applied to prebiotic products of parabacteroides probiotics.

The present invention provides a homogenized pumpkin polysaccharide and its preparation method and application, belonging to the technical field of polysaccharide extraction and purification. The homogenized pumpkin polysaccharide of the present invention contains mannose, glucosamine hydrochloride, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose, with the corresponding molar ratios being 0.005:0.004:0.041:0.013:0.545:0.004:0.241:0.147; the relative molecular weight of the homogenized pumpkin polysaccharide is 5.96×10 4 The homogenized pumpkin polysaccharide has significant lipid-lowering and blood sugar-lowering effects. The preparation method has mild process conditions and simple operation. The obtained polysaccharide has high purity and stable structure, and is suitable for industrial-scale production.

The invention discloses application of GUX1 protein and related biological materials thereof in regulation and control of xylan glucuronic acid modification. Through overexpression of GUX1 in rice and tobacco, the invention finds that the short interval substitution of xylan glucuronic acid in an acceptor material is specifically increased. According to the invention, the function of short-interval glucuronic acid addition of GUX1 mediated xylan is found for the first time, and the GUX1 gene can be used for regulating a glucuronic acid modification mode of plant xylan and producing a corresponding xylan structure product, and is an important and valuable gene for cell wall structure and function modification.